Kameta et al. performed cancer gene panel testing of 50 genes using EUS-FNA-derived frozen specimens for pancreatic cancer (n = 27) and detected KRAS mutations (96%), TP53 mutations (44%), CDKN2A mutations (11%), and SMAD4 mutations (7%), and they confirmed KRAS mutations using TaqMan PCR analysis [29]. This evidence concerns the gene CDKN2A and cancer.